A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Hereditary mutations associated with hematologic malignancies are rare. Heterozygous mutations affecting the hematopoietic transcription factor CBFA2 (also AML1/RUNX1) were recently reported to be associated with familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML, MIM 601399). A new 3-generation family with FPD/AML with a novel CBFA2 mutation is described. In this family, AML was diagnosed in a second-generation male. After allogeneic stem cell transplantation from his human leukocyte antigen–identical sister, a donor-derived, genetically identical leukemia developed in the recipient and the donor. Sequencing analysis identified a G-to-T transition within the CBFA2 gene, which involves codon 198, encoding a conserved aspartic acid within the DNA- binding Runt domain. Three of 5 siblings affected with the FPD/AML trait harbored the mutation in a heterozygous form. This experience underscores the necessity of performing mutation analysis of the CBFA2 gene before sibling allogeneic transplantation in families with FPD/AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100 · cited 2×
“II:1 Dec 1998 46,XY No 1 21 II:3 Dec 1998 46,XX BT II:4 Aug 1996 AML M1 92,XXYY, add(7)(q31), add(7)(q31)[14]/46,XY[10] Apr 1997 After BMT 46,XX Nov 1997 After BMT Sep 1998 Relapse/secondary leukemia? 47,XX,121[13]/47,XX,18[7]/46,XX[4] 1 21 (37%) II:7 Oct 1996 Donor 46,XX Oct 1998 MDS 46,XX BT Feb 1999 AML M1 46,XX BT…”
BackgroundPreudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J. L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000) · Blood · doi:10.1182/blood.v96.8.2862 · Cited by 263
Cited by
Core-binding factors in haematopoiesis and leukaemia
Speck, N. A., & Gilliland, D. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc840 · Cited by 569
Role of RUNX1 in hematological malignancies
Sood, R., Kamikubo, Y., & Liu, P. (2017) · Blood · doi:10.1182/blood-2016-10-687830 · Cited by 494
Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281
Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
Osato, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207779 · Cited by 268
Owen, C. J., Toze, C. L., Koochin, A., Forrest, D. L., Smith, C. A., Stevens, J. M., Jackson, S. C., Poon, M.-C., Sinclair, G. D., Leber, B., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156745 · Cited by 242
Metadata
- Authors
- Buijs, A., Poddighe, P., van Wijk, R., van Solinge, W., Borst, E., Verdonck, L., Hagenbeek, A., Pearson, P., & Lokhorst, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-11-01
- Volume
- 98
- Issue
- 9
- Pages
- 2856-2858
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2099405453
- Cited by
- 135
- References
- 2
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. https://app.cochat.ai/papers/10.1182/blood.v98.9.2856
- The paper
- Buijs, A., Poddighe, P., van Wijk, R., van Solinge, W., Borst, E., Verdonck, L., Hagenbeek, A., Pearson, P., & Lokhorst, H. (2001). A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood. https://doi.org/10.1182/blood.v98.9.2856
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.